T1	Participants 521 619	73 children aged less than 36 months who were admitted with a clinical diagnosis of whooping cough
T2	Participants 663 838	three groups: (a) monocomponent pertussis toxoid vaccine; (b) two-component acellular vaccine also containing filamentous haemagglutinin; or (c) 20% albumin solution (placebo)
T3	Participants 1036 1047	67 children
T4	Participants 1083 1156	47 children with less than or equal to 14 days of disease before therapy.
T5	Participants 1226 1266	the 33 children receiving immunoglobulin
T6	Participants 1298 1322	the 14 receiving placebo
